**Research Article**

**Evaluating plasma Digoxin concentration after an intravenous loading dose in patients with renal failure**

Vahid Eslami¹, Fatemeh Mortezapour², Shiva Samavat³, Shadi Ziae⁴ and Azin Gheymati⁵*

¹Assistant Professor of Cardiology, Shahid Beheshti University of Medical Sciences, Cardiovascular Research Center, Tehran, Iran  
²Shahid Beheshti University of Medical Sciences, Cardiovascular Research Center, Tehran, Iran  
³Department of Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
⁴Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
⁵Resident of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

**Abstracts**

**Background:** Digoxin is a medication of Glycoside family which is commonly prescribed for patients with atrial fibrillation, atrial flutter, and heart failure. With a narrow therapeutic level (0.5–2 ng/mL), careful monitoring of digoxin blood level is necessary. Symptoms of digoxin toxicity include nausea, vomiting, visual changes, altered mental status, hyperkalemia, and cardiovascular collapse. As renal failure decreases the clearance of digoxin, and impaired renal function is common in heart failure, this population is at higher risk of toxicity.

**Methods & materials:** In this prospective study, patients with chronic kidney disease- nondialysis (CKD-ND) who were admitted with heart failure or atrial fibrillation at university hospital, were enrolled. Digoxin-naive patients were treated with a 10 mcg/kg intravenous digoxin loading dose. Serum digoxin level was measured 6 to 12 hours after the last loading dose. Patients were followed for 48 hours for signs of toxicity. Correlation between therapeutic digoxin level and degree of renal failure was evaluated. The effect of serum electrolyte (magnesium, calcium, and potassium) concentration on digoxin level was determined. Pregnant women were excluded from study.

**Results:** From 2018 to 2020, 87 CKD patients, (60 (69%) men and 27 (31%) women) aged from 31 to 92 years old, with a mean age of 70.51 ± 14.06 years were admitted to the cardiac unit. Near 80% of the cohort were CKD stage 3 and 4 patients. About half of patients had digoxin levels in therapeutic range (45 cases = 51.7%), followed by 48 hours for signs of toxicity. Correlation between therapeutic digoxin level and degree of renal failure was evaluated. The effect of serum electrolyte (magnesium, calcium, and potassium) concentration on digoxin level was determined. Pregnant women were excluded from study.

**Conclusion:** this study demonstrated that monitoring plasma Digoxin concentration after an intravenous loading dose in patients with renal failure can be very helpful to prevent digoxin toxicity. The lower the GFR was, the higher the digoxin level and the risk for toxicity if the bolus and even maintenance do not monitor meticulously.

**Citation:** Eslami V, Mortezapour F, Samavat S, Ziae S, Gheymati A (2021) Evaluating plasma Digoxin concentration after an intravenous loading dose in patients with renal failure. Arch Clin Nephrol 7(1): 033-037. DOI: https://dx.doi.org/10.17352/acn.000053
**Introduction**

Digoxin is one of the frequently prescribed medications with a narrow therapeutic range and many drug interactions [1,2]. Increasing cardiac output and thereby decreasing ventricular filling pressures are the potential benefits of digoxin therapy in heart failure patients as a positive inotropic agent [3]. Plasma half-life range of digoxin varies from 20 to 50 hours, which is variable with a bioavailability of approximately 66%. Steady state plasma concentrations of digoxin are also altered proportionally to renal clearance of creatinine. The bioavailability and biotransformation of digoxin do not seem to vary between healthy subjects and patients with renal insufficiency. As the volume of distribution is smaller in patients with severe renal failure than normal subjects, the loading dose has to be altered. On the basis of this assumption, with decreasing creatinine clearance, the total body clearance as well as the renal clearance of digoxin is reduced [4].

In patients with renal failure, the half-life of digoxin increases, so that even in end-stage renal disease, it can be up to 4–6 days [5]. Due to the renal excretion of digoxin, renal dysfunction can lead to higher plasma concentrations and consequent toxicity. Renal failure, congestive heart failure, old age, and electrolyte abnormalities such as low potassium, phosphate, or calcium may worsen the condition [6].

Glomerular filtration damages in Chronic Renal Failure (CRF) constantly increase the risk of atherosclerosis and other heart diseases [7]. Oxidative stress also plays a central role in cardiovascular dysfunction. Evidence shows that uremia and hemodialysis in CRF increase levels of reactive oxygen species [8,9]. Thus, renal dysfunction is common in heart failure patients and can increase related mortality especially in GFR<60 ml/min [10]. Optimum Serum digoxin concentration (SDC) is supposed to be about 0.8 ng/mL, and it is essential to monitor its plasma concentration, particularly when ejection fraction falls below 45% [11,12]. Since Digoxin inhibits the sodium–potassium pumps and increases intracellular calcium in myocardial cells, patients with renal dysfunction are more prone to electrolyte imbalance in case of taking Digoxin [13]. Digoxin toxicity symptoms includes nausea, vomiting, visual changes, altered mental status, hyperkalemia, and cardiovascular collapse[14]. The mechanism and physiologically based pharmacokinetic of digoxin in renal failure are shown in the figures below (Figures 1, 2) [15].

Perceiving renal function during the treatment of heart failure using digoxin is necessary to prevent possible complications [16]. The purpose of this study is to assess the plasma Digoxin concentration after an intravenous loading dose in patients with renal failure. Also, this study evaluates the relationship between serum digoxin level with demographic and clinical characteristics including age, sex, serum electrolyte values (sodium, potassium, and magnesium), and creatinine level.

**Material and methods**

This prospective study was conducted in patients with...
Patients who had not consumed digoxin within 2 weeks before the loading dose and had received digoxin at a loading dose of 10 mcg/Kg (half of the total dose [5mcg/Kg] prescribed upon presentation and the resting half as a quarter [2.5 mcg/dl] every 6 hours) were included. Blood sample was drawn to assess digoxin concentration 6 to 12h after last digoxin administration. Patients with hypothyroidism (hypothyroidism or hyperthyroidism), renal replacement therapy, digoxin use in the last two weeks, acute renal failure, concomitant use of amiodarone, calcium channel blockers, quinine, quinidine, macrolides and cyclosporine consumption, weight over 120 kg, age under 18, pregnant women, death during the study and dissatisfaction with the study were excluded. EGFRA was calculated based on Cockcroft-Gault equation and lean body weight was considered in it. Patients were categorized into 4 groups according to GFR, including stage 2 (GFR>60), stage 3 (GFR: 30-60), stage 4 (GFR: 15-30) and stage 5 (GFR<15). Serum Digoxin level under 1.2 nmol/L was considered as therapeutic, between 1.2 to 2 nmol/L as Supra therapeutic, and above 2 nmol/L as toxic.

Patients were observed for 48 hours after receiving Digoxin loading dose since toxicity symptoms (including anorexia, nausea, vomiting, weakness, visual disturbances, or sinus bradycardia (< 60 bpm)) may occur if serum digoxin concentration increases to 2 nmol/L or above.

Demographic and clinical characteristics including age, sex, serum electrolyte values (sodium, potassium, and magnesium), and creatinine level were also recorded.

**Statistical analysis**

All variables were recorded in Statistical Package for the Social Sciences (SPSS), Version 25.0. Statistical Analysis was performed using the Pearson correlation. Statistical significance was considered as p ≤ 0.05 and the results were presented by using tables of distribution, frequency and percentages for categorical variables. Kai square, Fisher, T-test and independent multivariate analysis were used.

**Results**

During the study period, 87 patients aged 31 to 92 years, with a mean age of 70.51±14.06. years were enrolled. The patients consist of 60 (69%) men and 27 (31%) women. The most common underlying cardiac disorder was heart failure (9 patients, 10.3%). The mean serum digoxin concentration was measured as follows: stage 2 (0.65 ± 0.16 ng/mL), stage 3 (1.44 ± 0.63 ng/mL), stage 4 (1.73 ± 1.43 ng/mL) and stage 5 (1.57 ± 1.17 ng/mL).

There was a significant correlation between serum digoxin concentration and serum magnesium level (2.09 ± 0.30 meq/L) (p-value = 0.006), but other demographic and clinical characteristic including age, sex, GFR, serum sodium, potassium and creatinine values did not show any correlation with serum digoxin concentration.

Serum digoxin level was in therapeutic range in almost half of the patients (45 cases = 51.7%), while21 cases (24.1%) had supra therapeutic levels and toxic levels was observed in 21 cases (24.1%). Laboratory findings of different groups and correlation with Digoxin therapeutic concentration are shown in the Table 2. There was no significant differences between clinical signs of digoxin toxicity like nausea and vomiting between groups.

**Discussion**

Our study shows a significant correlation between the measured digoxin serum concentration with GFR (P value= 0.03) and Creatinine (p value= 0.04), while no correlation was found with age and gender. It was also shown that although there was a significant correlation between digoxin levels and magnesium and sodium levelin two groups, correlations with different stages of renal function (GFR) were not observed. These results are the same as reported in similar studies.

Digoxin, as a digitalis glycoside, improves the hemodynamic and neurohormonal perturbations which plays a crucial role in Heart Failure (HF) induced renal dysfunction. Abnormal energy metabolism increased production of reactive oxygen species (ROS), and defects in excitation–contraction are the hallmarks of Heart Failure due to impaired ventricular filling or blood ejection[19,20]. Digoxin increases intracellular calcium in myocardial cells and inhibits the sodium–potassium pump, besides, induces an increase in intracellular Na⁺ and Ca²⁺ [21]. However, our study did not show a significant relationship between sodium and potassium levels with digoxin levels, which may be due to minor changes in the levels of electrolytes. However, the difference in sodium levels between the two groups with Digoxin therapeutic and toxicity concentration, was significant.

A case–control study of patients who took digoxin for a long time and had a toxic level compared with those who recently received a therapeutic dose of digoxin reported that There were no differences between case and control groups with creatinine, age, or sex [22]. The findings show that there is a significant direct

**Table 1:** Correlation between serum digoxin concentration with demographic and clinical characteristic.

<table>
<thead>
<tr>
<th>Serum digoxin concentration</th>
<th>magnesium</th>
<th>creatinine</th>
<th>age</th>
<th>sex</th>
<th>GFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value= 0.006</td>
<td>p-value= 0.042</td>
<td>p-value= 0.3</td>
<td>p-value= 0.3</td>
<td>p-value= 0.038</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Comparison 3 groups with different therapeutic doses of digoxin

<table>
<thead>
<tr>
<th>GFR (mg/dl)</th>
<th>Na(mg/dl)</th>
<th>K(mg/dl)</th>
<th>Mg(mg/dl)</th>
<th>Cr(mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Digoxin therapeutic dose</strong></td>
<td>29.3 ± 17.69</td>
<td>140.53 ± 3.25</td>
<td>4.22 ± 0.40</td>
<td>2.01 ± 0.24</td>
</tr>
<tr>
<td><strong>Digoxin supra therapeutic dose</strong></td>
<td>30.71 ± 4.26 (P value = 0.1)</td>
<td>136.71 ± 5.78 (P value = 0.9)</td>
<td>4.35 ± 0.30 (P value = 0.1)</td>
<td>2.05 ± 0.40 (P value = 0.3)</td>
</tr>
<tr>
<td><strong>Digoxin toxicity dose</strong></td>
<td>26.00 ± 11.94 (P value = 0.7)</td>
<td>140.28 ± 3.74 (P value = 0.0)</td>
<td>4.28 ± 0.19 (P value = 0.5)</td>
<td>2.28 ± 0.24 (P value = 0.0)</td>
</tr>
</tbody>
</table>

link between magnesium and digoxin. These results were inconsistent with the 1991 study by Young IS et al that examined the relationship between serum magnesium levels and digoxin toxicity. Results demonstrated that magnesium deficiency was the most common electrolyte disorder associated with digoxin toxicity [23].

The results of this study show the importance of monitoring patients receiving a loading dose of digoxin and have renal dysfunction. About 30 to 50% of Patients with heart failure suffer from kidney dysfunction. Inflammation, oxidative stress, impaired hydro saline homeostasis, and diuretic resistance are common mechanisms in heart failure and kidney dysfunction which lead to worsen diseases prognosis [24]. In Testani JM, et al study, patients who suffered from impaired renal failure, digoxin was associated with survival benefit in patients significantly (adjusted hazard ratio=0.49, 95% CI 0.3–0.8; P = .006; P interaction = .026) [25]. Also The results of a study by Voors, AA, et al. in 2011 showed renal dysfunction with decreased glomerular filtration rate and increased serum creatinine, raised mortality and hospitalization in patients with cardiac disease and increased sodium and fluid retention also induced resistance to loop diuretics [26]. While heart failure progresses, decrease arterial pressure combined with an increase in venous pressure leads to glomerular filtration declines. Preventing the development of kidney damage in patients with cardiac disorders is a major challenge [27]. The glomerular filtration rate (GFR), serum electrolyte values and Creatinine levels are used to monitor chronic kidney disease [28]. GFR less than 10.0 ml per minute per 1.73 m² considers as end-stage renal disease and they are higher risk for cardiovascular events compared to other stages [29]. A study in 2018 introduced urea and serum creatinine as the best criteria for predicting mortality in patients with chronic digoxin poisoning [30].

A study in California of 41 patients receiving digoxin with blood urea nitrogen (RUN), 26.1 ± 12.8 mg per 100 ml; creatinine, 1.1 ± 0.041 mg per 100 ml; creatinine clearance, 78 ± 42 ml/min/1.73 m²; digoxin clearance, 66.6 ± 42.1 ml/min/1.73 m² indicated that digoxin has some degree of tubular reabsorption in addition to filtration and secretion [31]. Another study was done on 124 patients ranging in age from 22 to 88 years with serum creatinine ranged from 0.40 to 1.80 mg/dL (median 0.90 mg/dL, IQR 0.79, 1.10) and SDC was 1.12±0.34 mcg/L showed importance Prediction Of Serum Digoxin Concentration Using Estimated Glomerular Filtration Rate [32].

Drugs including amiodarone, verapamil, diltiazem, nifedipine, quinidine, quinine, clarithromycin, azithromycin, and erythromycin, tetracycline, and cyclosporine could influence digoxin concentration [33]. Hypokalemia, hypomagnesemia, hypercalcemia, myocardial ischemia, hypoxemia, and acid-base disturbances are conditions that increase the serum digoxin concentration which may cause toxicity. Long-term therapy with digoxin can lead to overdose and emergent condition [34,35]. Bradycardia and life-threatening ventricular arrhythmias are results of Digoxin toxicity. According to this, close observation in patients with Atrial Fibrillation or Heart Fibrillation and CKD is recommended [36]. The results of these studies confirm the result of the present study.

Our prospective study has some limitations because it was a Hospital-Based Study with a limited sample size and some of the data like causes of «toxic» digoxin concentrations are not available.

**Conclusion**

This study emphasize on importance of weight adjusted dose selection of digoxin not only in the maintenance dose but also in the bolus dose and demonstrated that monitoring plasma Digoxin concentration after an appropriate and measured intravenous loading dose in patients with renal failure can be very helpful to prevent digoxin toxicity. By checking the serum level of digoxin during treatment and the level of serum electrolytes, including magnesium, it can be ensured that no digoxin poisoning will occur, and in cases with digoxin toxic symptoms, the necessary procedures are taken.

**References**


